@JCO_ASCO: TURBO-NSCLC ( was a multi-institutional cohort study of 317 treatment-naive EGFR or ALK NSCLC pts with Brain Mets who received TKI w/wo up-front SRS. SRS was associated with superior CNS control. @MSK_RadOnc.@MSKCancerCenter.

RT @SimonLo21054188: Consensus Radiation Treatment Planning Guidelines Using (68)Ga-DOTATATE PET/CT For Resected Meningiomas - Internationa….

RT @JAMAOnc: The management of brain metastases in EGFR-variant and ALK-positive NSCLC patients remains uncertain, with evidence suggesting….

I’m pleased to share our summary of the clinical evidence on the use of TKIs and SRS in EGFR or ALK+ NSCLC! We need better biomarkers to select patients for treatment de-escalation. @JAMAOnc @MSKCancerCenter @MSK_RadOnc .

RT @Chad_Rusthoven: What is the optimal integration of SRS and CNS-active TKIs for brain metastases from EGFR & ALK+ NSCLC?. New @JAMAOnc c….

The ICON-RT study is now active at MSK! In this ph2 RCT, we seek to test a treatment de-escalation strategy for EGFR+LC Brain Mets through Intracranial CONsolidation with RT after a lead-in of osimertinib-based therapy! @MSKCancerCenter @MSK_RadOnc

I'm pleased to share work led by Ben Gaeta and Jordan Eichholz @jeeichholz on CNS outcomes and genomic correlates of KRAS mutant NSCLC Brain Mets treated with SRS, published in the Red J! @MSKCancerCenter @MSK_RadOnc @IJROBP

@HockemeyerKate @MSKCancerCenter @MSK_RadOnc @Cancers_MDPI An congratulations to @HockemeyerKate for making the cover!.

I am very pleased to partner with @HarbingerHlth in our combined goal of making blood-based early cancer detection a reality! @MSKCancerCenter @MSK_RadOnc .

RT @CD_AACR: From the November issue: Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detect….

Very fine review written by Dr. @HockemeyerKate , one of our star resident physicians at @MSKCancerCenter @MSK_RadOnc on the management of lung cancer brain metastasis, now online at @Cancers_MDPI .

We're hiring again this year for an MSK CNS Fellow! Please directly inquire if interested!.

RT @NiuSanford: 4 years residency, friends for life ❤️ . #HROP #ASTRO24

Proud to see work led by Chengcheng Gui and @hswalch published in @TheJNS in which we examine radiosurgical outcomes in a large cohort of CRC BM patients. Dose matters here and we identify putative genomic biomarkers. @MSKCancerCenter @MSK_RadOnc

Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic Radiosurgery - European Urology Oncology

Online now at @EurUrolOncol is exciting work by @JenniferMaMD @LukedelBalzo @hswalch, co-mentored with @KotechaMD. The largest series of RCC BM genomics, identifying genomic biomarkers correlated with CNS outcome after SRS. @MSKCancerCenter @MSK_RadOnc .

RT @JoeChangMD: Any role of up-front SRS in lung pts with brain Mets and EGFR or ALK targetable mutations who is receiving the 3th generati….

RT @Chad_Rusthoven: Also want to mention my gratitude for the opportunity to work on this study w/ outstanding collaborator & lead author L….

RT @MSKCancerCenter: A new multi-institution study from @pike_lab and colleagues in @JCO_ASCO finds adding up-front stereotactic radiosurge….

RT @MSK_RadOnc: 🧠⚡️🫁☢️New in @JCO_ASCO from @pike_lab @Chad_Rusthoven: The addition of up-front #radiation #SRS to CNS-penetrant #TKI ⬆️tim….

RT @PDBrownOnc: Any benefit w/ upfront SRS for EGFR and ALK positive NSCLC brain Mets treated w/CNS penetrant TKI?.· ↑↑LC and CNS control.·….